Related Experiment Video
Updated: Apr 29, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
Published on: April 13, 2015
NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem
Filippos Kottakis1, Parthena Foltopoulou1, Ioannis Sanidas1
1Authors' Affiliation: Molecular Oncology Research Institute, Tufts Medical Center, Boston, Massachusetts.
Abstract:
The JmjC domain histone H3K36me2/me1 demethylase NDY1/KDM2B is overexpressed in various types of cancer. Here we show that knocking down NDY1 in a set of 10 cell lines derived from a broad range of human tumors inhibited their anchorage-dependent and anchorage-independent growth by inducing senescence and/or apoptosis in some and by inhibiting G1 progression in all. We further show that the knockdown of NDY1 in mammary adenocarcinoma cell lines decreased the number, size, and replating efficiency of mammospheres and downregulated the stem cell markers ALDH and CD44, while upregulating CD24. Together, these findings suggest that NDY1 is required for the self-renewal of cancer stem cells and are in agreement with additional findings showing that tumor cells in which NDY1 was knocked down undergo differentiation and a higher number of them is required to induce mammary adenocarcinomas, upon orthotopic injection in animals. Mechanistically, NDY1 functions as a master regulator of a set of miRNAs that target several members of the polycomb complexes PRC1 and PRC2, and its knockdown results in the de-repression of these miRNAs and the downregulation of their polycomb targets. Consistent with these observations, NDY1/KDM2B is expressed at higher levels in basal-like triple-negative breast cancers, and its overexpression is associated with higher rates of relapse after treatment. In addition, NDY1-regulated miRNAs are downregulated in both normal and cancer mammary stem cells. Finally, in primary human breast cancer, NDY1/KDM2B expression correlates negatively with the expression of the NDY1-regulated miRNAs and positively with the expression of their PRC targets.
Insights
The histone demethylase NDY1/KDM2B promotes cancer growth and stem cell self-renewal. Inhibiting NDY1 halts tumor growth by affecting cell cycle progression and differentiation, offering a potential therapeutic target.
Area of Science:
- Epigenetics and Cancer Biology
- Stem Cell Biology
- Gene Regulation
Background:
- The JmjC domain histone demethylase NDY1/KDM2B is frequently overexpressed in diverse human cancers.
- NDY1/KDM2B plays a role in regulating gene expression through histone modification.
Purpose of the Study:
- To investigate the role of NDY1/KDM2B in cancer cell proliferation, self-renewal, and differentiation.
- To elucidate the molecular mechanisms by which NDY1/KDM2B influences cancer stem cell properties.
Main Methods:
- Knockdown of NDY1 in various human cancer cell lines.
- Assessment of anchorage-dependent and independent growth, senescence, apoptosis, and cell cycle progression.
- Analysis of mammosphere formation and stem cell marker expression (ALDH, CD44, CD24).
- Orthotopic injection of modified tumor cells in animal models.
- Investigation of miRNA regulation and polycomb complex targeting.
- Correlation analysis of NDY1/KDM2B, miRNA, and polycomb target expression in human breast cancer tissues.
Main Results:
- NDY1 knockdown inhibited cancer cell growth, induced senescence/apoptosis, and blocked G1 progression across multiple tumor types.
- NDY1 inhibition reduced mammosphere formation and altered stem cell marker expression, suggesting impaired cancer stem cell self-renewal.
- NDY1 knockdown led to miRNA de-repression, targeting polycomb complexes (PRC1/PRC2), and promoted tumor cell differentiation.
- Overexpression of NDY1/KDM2B in triple-negative breast cancer correlated with relapse rates, and its expression inversely correlated with NDY1-regulated miRNAs in primary tumors.
Conclusions:
- NDY1/KDM2B is essential for cancer stem cell self-renewal and tumor growth.
- NDY1 acts as a master regulator of miRNAs targeting polycomb complexes, influencing cancer cell plasticity.
- Targeting NDY1/KDM2B represents a potential therapeutic strategy for cancers, particularly triple-negative breast cancer.
Related Concept Videos
Master Transcription Regulators
Abnormal Proliferation
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Negative Regulator Molecules
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

